Guys, the recent sec filing is clear. NASDAQ panel will grant continual list only if RS pass or somehow SP goes above 1$ for 10 days before Nov 15. That's very little time from now. So I won't count on SP to go above 1$, it would have to happen by Nov 5th two weeks from now.
So RS result being pushed back to 10/27 determines whether or not company stay on NASDAQ. SK is basically telling you, if you vote no, we all go to OTC.
If vote is still no, we potentially go even lower if we hit OTC. If vote is yes, RS will happen almost immediately. So short term prediction is bearish, but I am not saying long term it will not rise.
There are too much uncertainty such as will SK raise more capital after RS? How soon can NantCell file the NDA and set a PDUFA date for expected FDA approval on STS.
New combo study isn't really news that would add value right away. I'm still watching closely.